Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | DAO | P14920 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.38 |
| ▸ | NAMPT | P43490 | 8/20 | 0.36 |
| ▸ | MERTK | Q12866 | 4/20 | 0.36 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | RET | P07949 | 1/20 | 0.34 |
| ▸ | AXL | P30530 | 3/20 | 0.34 |
| ▸ | FLT3 | P36888 | 3/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.34 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11433529 | 0.82 | KEAP1 (0.57) | KEAP1MEN1CYP1A2KMT2ADAO | |
| SCHEMBL13140971 | 0.74 | KEAP1 (0.67) | KEAP1MEN1CYP1A2KMT2ADAO | |
| SCHEMBL3476854 | 0.71 | NSD2 (0.53) | KEAP1MEN1CYP1A2KMT2ADAO | |
| SCHEMBL11534498 | 0.71 | KEAP1 (0.49) | KEAP1CYP1A2DYRK1ARET | |
| SCHEMBL14638727 | 0.70 | LTA4H (0.48) | KEAP1CYP1A2CYP2C9 | |
| SCHEMBL24494597 | 0.69 | KEAP1 (0.68) | KEAP1MEN1CYP1A2KMT2ADAO | |
| SCHEMBL6092812 | 0.69 | KEAP1 (1.00) | KEAP1MEN1CYP1A2KMT2ADAO | |
| SCHEMBL74518 | 0.69 | KEAP1 (0.68) | KEAP1MEN1CYP1A2KMT2ADAO | |
| SCHEMBL2535366 | 0.69 | KEAP1 (0.68) | KEAP1MEN1CYP1A2KMT2ADAO | |
| SCHEMBL14554770 | 0.69 | KEAP1 (0.68) | KEAP1MEN1CYP1A2KMT2ADAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170204095-A1 | (1-AZINONE)-SUBSTITUTED PYRIDOINDOLES | APOLLO ADMINISTRATIVE AGENCY LLC, AS SUCCESSOR AGENT | 2017-07-20 | — | — | US | disclosed |
| US-20160159798-A1 | (1-AZINONE)-SUBSTITUTED PYRIDOINDOLES | HARMONY BIOSCIENCES, LLC | 2016-06-09 | — | — | US | disclosed |
| US-9296743-B2 | (1-azinone)-substituted pyridoindoles | ALBANY MOLECULAR RESEARCH, INC. (US) | 2016-03-29 | — | — | US | disclosed |
| EP-2476680-B1 | (1-Azinone)-Substituted Pyridoindoles | ALBANY MOLECULAR RES INC (US) | 2014-08-27 | — | — | EP | disclosed |
| US-20140206696-A1 | (1-AZINONE)-SUBSTITUTED PYRIDOINDOLES | ALBANY MOLECULAR RESEARCH, INC. (US) | 2014-07-24 | — | — | US | disclosed |
| US-8716308-B2 | (1-azinone)-substituted pyridoindoles | ALBANY MOLECULAR RESEARCH, INC. (US) | 2014-05-06 | — | — | US | disclosed |
| EP-2476680-A1 | (1-Azinone)-Substituted Pyridoindoles | Albany Molecular Research, Inc. (US) | 2012-07-18 | — | — | EP | disclosed |
| CN-101945872-A | (1-azinone) -substituted pyridoindoles as mch antagonists | ALBANY MOLECULAR RES INC | 2011-01-12 | — | — | CN | disclosed |
| US-20100331339-A9 | (1-AZINONE)-SUBSTITUTED PYRIDOINDOLES | ALBANY MOLECULAR RESEARCH, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20090275590-A1 | (1-AZINONE)-SUBSTITUTED PYRIDOINDOLES | ALBANY MOLECULAR RESEARCH, INC. (US) | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331339-A9 | (1-AZINONE)-SUBSTITUTED PYRIDOINDOLES | NR3C2, NR0B1, NR3C1 | KEAP1 2361/4885MEN1 1734/4885CYP1A2 294/4885 |
| US-20170204095-A1 | (1-AZINONE)-SUBSTITUTED PYRIDOINDOLES | NR3C2, NR2E3, NR0B1 | KEAP1 2441/4885MEN1 1448/4885CYP1A2 290/4885 |
| US-20090275590-A1 | (1-AZINONE)-SUBSTITUTED PYRIDOINDOLES | NR3C2, NR0B1, NR3C1 | KEAP1 2361/4885MEN1 1734/4885CYP1A2 294/4885 |
| US-20140206696-A1 | (1-AZINONE)-SUBSTITUTED PYRIDOINDOLES | NR3C2, NR2E3, NR0B1 | KEAP1 2441/4885MEN1 1448/4885CYP1A2 290/4885 |
| US-20160159798-A1 | (1-AZINONE)-SUBSTITUTED PYRIDOINDOLES | NR3C2, NR2E3, NR0B1 | KEAP1 2441/4885MEN1 1448/4885CYP1A2 290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.